Industry Expectations for Early-Stage Innovation and Academic Partnerships

Great to see the Bio Integrates 2026 Industry Intelligence Report now live, following an event we were proud to support - with our very own James FRY and Isabel Teare hosting panel sessions. Thank you Life Science Integrates for including us again! A few themes emerging.... - The sector feels like it’s moving from survival into a more cautious recovery, with capital returning but under much tighter scrutiny. - Patient impact is no longer a ‘nice to have’ – it needs to be built in from day one. - Collaboration is shifting from optional to essential, especially with the rise of AI-led partnerships. Strong science still matters, of course, but it’s now about pairing that with resilience, clear strategy and real-world relevance. If you didn’t get a chance to attend, the full report is well worth a read: https://lnkd.in/eQ9RK3E8 #BioIntegrates #Biotech #LifeSciences #FutureofHealth

Biotech teaches you humility very quickly. You can spend months building the perfect experiment… and then discover that a tiny change in temperature, timing or material behavior changes everything. What worked beautifully in the lab suddenly becomes unstable during scale-up. Results stop reproducing. Variability appears. And the team realizes the science was only part of the challenge. Many biotech failures are not caused by bad science. They happen because the process was never truly understood well enough to become repeatable. Because in biotechnology, success is not only about innovation. It’s about creating enough process understanding and control to reproduce that innovation reliably. That’s where biology becomes engineering. What has been the biggest challenge or surprise your team faced during research, development or scale-up? ScaleUp InnoVest #Biotech #ScaleUp #ProcessDevelopment #Biology #MedTech #Manufacturing

At a certain stage, life sciences companies face a subtle but important narrative transition. Early on, the story is driven by innovation: • breakthrough science • novel platforms • technical differentiation • possibility But as companies mature, the external evaluation changes. The conversation gradually shifts toward: • trust • scalability • commercial readiness • operational credibility • long-term viability The challenge is that many organizations continue communicating like innovation-stage companies long after stakeholders begin evaluating them differently. That transition often shapes commercialization outcomes more than teams initially realize. #LifeSciences #Biotech #Commercialization #StrategicPositioning

Get insights into the latest developments in the Life Sciences & Health sector with BiotechNews!   BiotechNews is a leading media platform covering the Dutch and Belgian ecosystem, sharing sector updates, in-depth stories, interviews, and industry movements across biotech, pharma, medtech, academia, and investment.   𝗛𝗲𝗿𝗲 𝗮𝗿𝗲 𝘀𝗼𝗺𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗹𝗮𝘁𝗲𝘀𝘁 𝗮𝗿𝘁𝗶𝗰𝗹𝗲𝘀:   ⚪ 𝘞𝘦 𝘩𝘢𝘷𝘦 𝘢𝘭𝘭 𝘵𝘩𝘦 𝘳𝘪𝘨𝘩𝘵 𝘪𝘯𝘨𝘳𝘦𝘥𝘪𝘦𝘯𝘵𝘴 – 𝘸𝘩𝘺 𝘭𝘦𝘵 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘸𝘢𝘪𝘵? Schuttelaar & Partners interviews Michel van Agthoven (Johnson & Johnson) and Hans Schikan (former Top Team member Health Holland) during Innovation for Health, exploring the gap between innovation and patient access. https://lnkd.in/e6ZF_zDX   ⚪ 𝘗𝘢𝘳𝘵𝘯𝘦𝘳𝘴𝘩𝘪𝘱 𝘳𝘦𝘴𝘶𝘭𝘵𝘴 𝘪𝘯 𝘧𝘶𝘭𝘭-𝘴𝘦𝘳𝘷𝘪𝘤𝘦 𝘢𝘨𝘦𝘯𝘤𝘺 𝘸𝘪𝘵𝘩𝘪𝘯 𝘓𝘪𝘧𝘦 𝘚𝘤𝘪𝘦𝘯𝘤𝘦𝘴 Discover how CLS Services and MY Recruitment are joining forces to strengthen their position in international life sciences recruitment. https://lnkd.in/edMQXQVJ ⚪ ‘𝘛𝘩𝘦 𝘪𝘯𝘥𝘶𝘴𝘵𝘳𝘺 𝘥𝘰𝘦𝘴𝘯'𝘵 𝘤𝘢𝘳𝘦 𝘢𝘣𝘰𝘶𝘵 𝘺𝘰𝘶𝘳 𝘱𝘢𝘱𝘦𝘳𝘴’ - 𝘐𝘴𝘢𝘣𝘦𝘭𝘭𝘦 𝘒𝘰𝘩𝘭𝘦𝘳 𝘰𝘯 𝘵𝘩𝘦 𝘴𝘬𝘪𝘭𝘭𝘴 𝘵𝘩𝘢𝘵 𝘗𝘩𝘋𝘴 𝘢𝘤𝘵𝘶𝘢𝘭𝘭𝘺 𝘯𝘦𝘦𝘥. Learn how Isabelle Kohler founded NextMinds to help PhD students transition into the biotech and biopharmaceutical industry. https://lnkd.in/euQ8fGnd ⚪HAN BioCentre 𝘱𝘢𝘳𝘵𝘯𝘦𝘳 𝘪𝘯 𝘎𝘳𝘰𝘦𝘪𝘧𝘰𝘯𝘥𝘴 𝘊𝘦𝘭𝘭𝘶𝘭𝘢𝘪𝘳𝘦 𝘈𝘨𝘳𝘪𝘤𝘶𝘭𝘵𝘶𝘶𝘳 𝘦𝘯 𝘍𝘶𝘯𝘨𝘊𝘰𝘸𝘴. Explore how the project is developing sustainable alternatives for dairy, meat, and fish proteins using microorganisms instead of animals. https://lnkd.in/eHR9sxeq → Explore more stories and sector updates here: https://biotechnews.nl/   Do you want to share your story with a targeted life sciences audience? Get featured on BiotechNews and increase your visibility within the ecosystem: https://lnkd.in/eGvGNQQp   📩 Follow BiotechNews and subscribe to the newsletter to stay informed about the latest developments in the sector: https://lnkd.in/eCTMEK4Z   #biotech #lifesciences #innovation #pharma #medtech

When I was doing my PhD and spending most of my time in the lab, what fascinated me most about biotech was obviously the science itself. Seeing a mutant protein work, understanding a biological mechanism… that was the exciting part. Over the last few years, after moving progressively closer to the business and manufacturing side of biotech, I’ve started appreciating something else that probably receives much less attention from the outside: how difficult it actually is to transform good science into something robust, scalable and sustainable. And recently, while reading more and more news around advanced therapies, manufacturing expansions, regulatory challenges or biotech restructurings, I sometimes get a similar feeling again. Not that the science is becoming less important (far from it!) but that many of these fields are starting to collide with the practical side of biotech. Manufacturing, reproducibility, scalability, supply chain or regulatory execution may not be the most exciting part scientifically, but at some point they become impossible to separate from the science itself. I guess one thing I’ve learned over time is that biotech probably needs both perspectives much more than I initially thought; the excitement of discovery itself, but also the ability to make those technologies robust, reproducible and scalable enough to survive real-world application. #biotech #biomanufacturing #GMP #proteins #advancedtherapies

#BBI #Insights continues to explore how life sciences #innovation moves beyond scientific discovery and into real-world impact. In our latest reflection, we ask a central question: When does scientific discovery become an investable opportunity? Turning strong science into #real-#world value requires more than innovation alone. It demands strategic clarity, translational thinking, deep market understanding, and the ability to align scientific potential with the realities of execution and #long-#term #investment. Read more: https://lnkd.in/eXmpEgu8 Through BBI Insights, we aim to foster dialogue around the challenges and opportunities shaping the future of #LifeSciences and #healthcare #innovation. Contribution: Mark Treherne, Chris Howie. #BBICambridge #BBIInsights #LifeSciences #Biotech #HealthcareInnovation #InnovationStrategy #VentureCreation

Several years on a rollercoaster, but it’s finally official: We have been granted a patent in Mexico! 🇲🇽 (And the US process is already moving). To explain it in easy mode: We developed a matrix for oral probiotics so they can act directly in the mouth to fight cavities, bad breath, and other oral issues—without needing lyophilization (freeze-drying). Why does this matter? Normally, probiotics are put into a sort of "hibernation" and only activate once they reach your gut. Our tech changes that. It uses saliva enzymes to activate them on the spot, making the action localized and way more efficient right where oral diseases start. This started in 2018 as an ITESO university project. We finished the core research in 2020, and since then, it’s been a wild ride: building Sicte Biotek, navigating a pandemic, legal hurdles, and honestly, the most difficult barrier: dealing with the collaboration with the university. It took an immense amount of time, money, and energy. When you graduate, nobody teaches you how intellectual property actually works. It’s a huge gap that universities desperately need to bridge for young founders. But today, the milestone is hit. The technology is validated and ready for the next level. We are officially open to collaborations, partners, and strategic alliances to take this further. Let’s connect! 🚀 Link: https://lnkd.in/duSAT66h #Biotech #innovation #oralhealth #entrepeneurship #deeptech #probiotics

www.biosniffbiotech.com Mr.360 problem solving service...🇮🇳, The field of blue biotechnology should stop at mere research papers and start becoming solutions that are deployable, scalable, and applicable to industry as well. At biosniffbiotech, our goal is to make your biotech innovations into an ecosystem of products, which involves: • Artificial intelligence validation and intelligence components • Real-life prototype development • Systems for execution based on SOP • Standardized lab manuals • Deployability frameworks By doing so, biosniffbiotech bridges the gap from the scientific innovations of biotechnology to its industrial and business application. We are not simply working with innovations. We are creating deployable solutions for blue biotechnology. #BlueBiotechnology #Biosniffbiotech #Biotechnology #AIinBiotech

“Life is the most sophisticated manufacturing platform that has ever existed. It scales, it self-repairs, it runs on carbon and sunlight.” That is how Ola (Aleksandra) Wlodek , CEO of Constructive Bio, frames one of the most ambitious bets in synthetic biology. Ola (Aleksandra) Wlodek will be speaking at SynBioBeta 2026, May 4-7th in San Jose, California, you can learn more about the conference and get your tickets here: https://lnkd.in/gkMTHA5e Constructive Bio is building on two decades of work from Jason Chin’s lab on whole-genome writing and engineered translation. Its Syn61 strain rewrote the E. coli genome with more than 18,000 precise codon replacements, freeing three sense codons for non-canonical amino acids. The goal is not just scientific elegance. It is industrial manufacturing. Constructive Bio wants to make complex peptides and proteins in recoded organisms, including therapeutic molecules that are currently difficult, expensive, or waste-intensive to produce through conventional chemistry. The GLP-1 class is a powerful example. Drugs like semaglutide are produced by solid-phase peptide synthesis, a process associated with enormous chlorinated waste streams. Constructive’s pitch is that engineered biology can offer a cleaner, scalable, programmable alternative. This is why Ola’s perspective matters now. The company has raised $75 million to date, is advancing pharma partnerships, and is preparing a next-generation recoded strain designed for greater robustness and scalability in industrial fermentation. This is also why being in the room matters. Relationships are built in the room. Deals happen in the room. Breakthroughs happen in the room. At #SynBioBeta, the people building the next generation of therapeutic manufacturing will be sitting across from the investors, partners, and builders who can help bring it to scale. Visit the SynBioBeta website to read the full article: https://lnkd.in/gk9HmBMG

Our CEO Chris Hollowood has been on BioCentury Inc. TV to describe how unbiased approaches to target ID are an important guide in investment decision making at Syncona Limited and Slingshot Therapeutics